Paula R Pohlmann
Overview
Explore the profile of Paula R Pohlmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reiss K, Angelos M, Dees E, Yuan Y, Ueno N, Pohlmann P, et al.
Nat Med
. 2025 Feb;
PMID: 39920391
Chimeric antigen receptor (CAR) macrophages (CAR-Ms) mediate antitumor immunity via phagocytosis, cytokine release, activation of the tumor microenvironment and antigen presentation. We report results from a non-prespecified interim analysis of...
2.
Heeke A, Elliott A, OKeefe K, Livasy C, Symanowski J, Steiner M, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2300719.
PMID: 39889242
Purpose: Alterations in human epidermal growth factor receptor 2 (HER2; gene) may be clinically relevant when considering HER2-targeted therapies. We have characterized the breadth of alterations (mutation, fusion, and copy...
3.
Gouda M, Gonugunta A, Dumbrava E, Yap T, Rodon J, Piha-Paul S, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39841861
Purpose: Trastuzumab deruxtecan (T-DXd) is currently approved for treating metastatic breast cancer (MBC) which is HER2-positive (immunohistochemistry [IHC] score of 3+ or ISH positivity) or HER2-low (IHC score of 1+...
4.
Okines A, Curigliano G, Mizuno N, Oh D, Rorive A, Soliman H, et al.
Nat Med
. 2025 Jan;
PMID: 39825152
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer....
5.
Tarantino P, Tayob N, Villacampa G, Dang C, Yardley D, Isakoff S, et al.
J Clin Oncol
. 2024 Jun;
42(31):3652-3665.
PMID: 38935923
Purpose: Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet...
6.
Lindgren E, Yan R, Cil O, Verkman A, Chan M, Seitzman G, et al.
Curr Ophthalmol Rep
. 2024 May;
12(2):13-22.
PMID: 38756824
Purpose Of Review: This study is to highlight the incidence of corneal pseudomicrocysts in FDA-approved antibody-drug conjugates (ADCs), and success of preventive therapies for pseudomicrocysts and related ocular surface adverse...
7.
Chen W, Ballman K, Partridge A, Hahn O, Briccetti F, Irvin W, et al.
JAMA
. 2024 Apr;
331(20):1714-1721.
PMID: 38683596
Importance: Observational studies of survivors of breast cancer and prospective trials of aspirin for cardiovascular disease suggest improved breast cancer survival among aspirin users, but prospective studies of aspirin to...
8.
DiPeri T, Evans K, Wang B, Zhao M, Akcakanat A, Raso M, et al.
Cancer Discov
. 2024 Feb;
14(5):828-845.
PMID: 38358339
Significance: We demonstrate that PDXs can be developed from pretreatment and postprogression biopsies in clinical trials and may represent a powerful preclinical tool. We identified amplification of MET as a...
9.
Gallagher R, Wulfkuhle J, Wolf D, Brown-Swigart L, Yau C, OGrady N, et al.
Cell Rep Med
. 2023 Dec;
4(12):101312.
PMID: 38086377
Molecular subtyping of breast cancer is based mostly on HR/HER2 and gene expression-based immune, DNA repair deficiency, and luminal signatures. We extend this description via functional protein pathway activation mapping...
10.
Roy T, Barrows E, Mainor C, Collins J, Lynce F, Isaacs C, et al.
Contemp Clin Trials Commun
. 2023 Apr;
33:101110.
PMID: 37026029
Standard treatment for metastatic hormone positive (HR+) breast cancer includes a combination of a CDK4/6 inhibitor and antiestrogen therapy. Despite durable responses, eventual endocrine resistance results in disease progression. The...